|
Market Closed -
Nasdaq
00:00:00 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 78.56 USD | -0.01% |
|
-8.63% | +18.37% |
| 10-26 | Leerink Partners Adjusts Price Target on DexCom to $87 From $94 | MT |
| 10-16 | HEALTH ROUNDS-Glucose monitoring devices for type 2 diabetes benefit even those not on insulin | RE |
Company Valuation: DexCom, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 52,042 | 43,740 | 47,945 | 30,377 | 25,885 | 29,645 | - | - |
| Change | - | -15.95% | 9.61% | -36.64% | -14.79% | 14.53% | - | - |
| Enterprise Value (EV) 1 | 52,692 | 45,068 | 49,813 | 31,073 | 26,209 | 28,884 | 28,584 | 27,769 |
| Change | - | -14.47% | 10.53% | -37.62% | -15.65% | 10.21% | -1.04% | -2.85% |
| P/E | 346x | 138x | 95.5x | 54.8x | 31.8x | 31.6x | 26.6x | 22.1x |
| PBR | 23.1x | 20.5x | 23.1x | 15.1x | 9.3x | 10.4x | 8.69x | 6.69x |
| PEG | - | 1x | 1.6x | 5.94x | 0.7x | 1.7x | 1.4x | 1.1x |
| Capitalization / Revenue | 21.3x | 15x | 13.2x | 7.53x | 5.55x | 5.67x | 5.12x | 4.6x |
| EV / Revenue | 21.5x | 15.5x | 13.8x | 7.7x | 5.62x | 5.52x | 4.93x | 4.31x |
| EV / EBITDA | 111x | 60x | 49.1x | 28.1x | 19.4x | 17.3x | 14.9x | 12.6x |
| EV / EBIT | 142x | 92.9x | 69.3x | 41x | 27x | 23.1x | 19.8x | 16.2x |
| EV / FCF | 989x | 148x | 97.3x | 49.3x | 24.3x | 28.3x | 23.4x | 18.9x |
| FCF Yield | 0.1% | 0.68% | 1.03% | 2.03% | 4.11% | 3.54% | 4.27% | 5.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.3875 | 0.82 | 1.3 | 1.42 | 2.09 | 2.489 | 2.952 | 3.562 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,448 | 2,910 | 3,622 | 4,033 | 4,662 | 5,228 | 5,794 | 6,446 |
| EBITDA 1 | 472.7 | 751.6 | 1,014 | 1,105 | 1,349 | 1,666 | 1,918 | 2,203 |
| EBIT 1 | 370.7 | 485.1 | 718.6 | 757.1 | 969.3 | 1,248 | 1,444 | 1,714 |
| Net income 1 | 154.7 | 341.2 | 541.5 | 576.2 | 836.3 | 973.1 | 1,146 | 1,401 |
| Net Debt 1 | 650.1 | 1,328 | 1,868 | 695.9 | 323.2 | -761.1 | -1,061 | -1,877 |
| Reference price 2 | 134.24 | 113.24 | 124.09 | 77.77 | 66.37 | 78.56 | 78.56 | 78.56 |
| Nbr of stocks (in thousands) | 387,688 | 386,258 | 386,374 | 390,595 | 390,016 | 377,361 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 31.57x | 5.53x | 17.34x | -.--% | 29.65B | |
| 34.7x | 4.1x | 15.76x | 2.47% | 181B | |
| 23.76x | 4.66x | 16.26x | 1.17% | 117B | |
| 20.26x | 3.52x | 12.6x | 2.99% | 116B | |
| 30.71x | 2.97x | 11.98x | 2.32% | 89.94B | |
| 18.1x | 0.21x | 13.1x | 0.72% | 62.97B | |
| 31.43x | 7.87x | 20.24x | 1.26% | 55.43B | |
| 38.95x | 3.6x | 12.25x | 2.13% | 53.49B | |
| 38.62x | 9.59x | 26.82x | -.--% | 44.92B | |
| 40.64x | 3.29x | 12.25x | 0.53% | 33.87B | |
| Average | 30.87x | 4.53x | 15.86x | 1.36% | 78.52B | |
| Weighted average by Cap. | 29.56x | 4.22x | 15.34x | 1.77% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXCM Stock
- Valuation DexCom, Inc.
Select your edition
All financial news and data tailored to specific country editions
